Press Releases May 20, 2026 04:05 PM

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Rapport Therapeutics to present at major upcoming healthcare investor conferences.

By Caleb Monroe RAPP

Rapport Therapeutics, a clinical-stage biotechnology firm focusing on small molecule precision medicines for neurological and psychiatric disorders, announced participation in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference with scheduled fireside chats in early June 2026. The company highlights its RAP technology platform and ongoing development pipeline, including RAP-219 and epilepsy-related programs.

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
RAPP

Key Points

  • Rapport Therapeutics will participate in two prominent healthcare investor conferences in June 2026 with live and archived webcasts available.
  • The company focuses on novel small molecule precision medicines targeting neurological and psychiatric disorders via its RAP technology platform.
  • Development pipeline includes lead investigational drug RAP-219 targeting epilepsy and bipolar mania, with additional programs in chronic pain, migraine, hearing, and vestibular disorders.
  • Impacted sectors include biotechnology, pharmaceuticals, healthcare technology, and neuroscience research.

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences.

Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:45 am ET.

Goldman Sachs 47th Annual Global Healthcare Conference (Miami, FL) – fireside chat on Monday, June 8, 2026, at 1:20 pm ET.

Interested parties may access the live and archived webcasts of these fireside chats under the “Investors” section of the company’s website at: https://investors.rapportrx.com.

About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company’s epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.

Investor Contact
Leigh Salvo
New Street Investor Relations
[email protected]


Risks

  • As a clinical-stage biotech company, product candidates like RAP-219 remain in development phases with inherent clinical and regulatory uncertainties.
  • Success depends on advancing multiple discovery and preclinical programs, which carry typical scientific and financial risks of failure or delay.
  • Market reception may be sensitive to clinical trial results, regulatory decisions, and competitive landscape in neurology and psychiatric drug development.

More from Press Releases

Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026 DLH Announces Filing of New Shelf Registration Statement Jun 4, 2026 FutureCorp Space Acquisition 1 Announces Pricing of $200,000,000 Initial Public Offering Jun 4, 2026